Trials / Conditions / Chromophobe Renal Cell Carcinoma

Chromophobe Renal Cell Carcinoma

14 registered clinical trials studyying Chromophobe Renal Cell Carcinoma — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer NCT07243067	Mayo Clinic	—
Recruiting	A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known NCT06805825	Novelty Nobility, Inc.	Phase 1
Recruiting	Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma NCT06318871	Dana-Farber Cancer Institute	EARLY_Phase 1
Active Not Recruiting	Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC NCT04413123	Bradley A. McGregor, MD	Phase 2
Active Not Recruiting	Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) f NCT04071223	National Cancer Institute (NCI)	Phase 2
Recruiting	An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Bi NCT04623502	University of Texas Southwestern Medical Center	N/A
Recruiting	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted NCT03866382	National Cancer Institute (NCI)	Phase 2
Completed	ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB) NCT03685448	Australian and New Zealand Urogenital and Prostate Cancer Trials Group	Phase 2
Active Not Recruiting	A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma NCT03635892	Memorial Sloan Kettering Cancer Center	Phase 2
Active Not Recruiting	Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue NCT06339138	Mayo Clinic	—
Active Not Recruiting	Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcino NCT03541902	M.D. Anderson Cancer Center	Phase 2
Unknown	Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Meta NCT03177239	Australian and New Zealand Urogenital and Prostate Cancer Trials Group	Phase 2
Completed	Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer NCT01767636	Mayo Clinic	Phase 2
Completed	Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer NCT00126503	National Cancer Institute (NCI)	Phase 1 / Phase 2